L’Oréal bets on digital-first India with Innovist majority stake
L’Oréal has signed an agreement to acquire a majority stake in Innovist, a digital-first Indian personal care house of brands. The strategic move is part of L’Oréal’s planned expansion in India’s fast-growing beauty industry.
StockWatch: Positive Phase III Data Sells Investors on Intellia
A second positive Phase III data readout in two months is a major reason why Intellia Therapeutics (Nasdaq: NTLA) shares have soared more than 76% over the past six months—including a 29% surge this past week that followed the CRISPR gene editing therapy developer’s lead pipeline candidate lonvoguran ziclumeran (lonvo-z) meeting three key secondary endpoints in a pivotal study in patients with hereditary angioedema (HAE).
40 Food Security Trailblazers Recognized by World Food Prize Foundation in Top Agri-food Pioneers List
June 2026, US: A total of 40 scientists, policymakers, community builders and innovators transforming food systems acros…
One Solution, Multiple Options: MULTIMAX MP 527 is the BKT Solution for a Variety of Challenging Operations
Balkrishna Industries Ltd., a global leader in Off-Highway tires, has a multi-purpose solution specifically designed for compact equipment such as wheel loaders, backhoe loaders and telehandlers facing diverse challenges in construction and agri-industrial applications. MULTIMAX MP 527 is BKT Tires’ response to the demands of complex environments–typically characterized by heavy loads, a high center of gravity, rough terrains, narrow maneuvering spaces–where reliable, versatile, and adaptable tires are essential.
Stratum Nutrition gains authorization in Canada for Ovolux skin health claims
Stratum Nutrition’s eggshell membrane ingredient for beauty-from-within applications, Ovolux, has achieved authorization for multiple skin health claims from Health Canada.
Pacifico Biolabs: “We Could Produce Enough Mycelium to Replace All European Chicken Consumption Using Idle Brewery Capacity”
Zac Austin is co-founder and CEO of Pacifico Biolabs. After graduating from the University of Cambridge, he began his career at McKinsey in London, working as a consultant across a range of industries. In 2020, he joined the UK Government’s Covid Task Force as Assistant Director in the Cabinet Office, focusing on national healthcare. The following year, he moved to Berlin to take on the role of Head of Special Projects at Razor Group, building and optimising operational teams and functions, before co-founding Pacifico Biolabs with Washington Logroño in November 2022.
AgriFood Signals: Anthropic joins carbon removal coalition, Elanco launches venture arm, AeroFarms acquired
AgFunderNews rounds up the most important fundings, mergers, acquisitions, closures, and industry buzz in agtech and foo…
仿制药压境!砜吡草唑之后,组合化学要如何续写增长故事?
世界农化网中文网报道:近期,日本组合化学(Kumiai Chemical)公布了2026财年第二季度经营业绩。结合一季度数据来看,2026财年上半年(2025年11月至2026年4月)净销售额同比增长7%,营业利润同比增长11%,经常利润同比大增66%,归母净利润同比增长39%。
The Naming Patterns Behind 12,000 Biotech Companies
Earlier this month Labiotech published its roundup of the top biotech deals for May 2026. Heading the list was Angelini Pharma’s $4.1 billion acquisition of Catalyst Pharmaceuticals, just ahead of UCB’s acquisition of Candid Therapeutics for $2.2 billion. For its part, Lilly also acquired Curevo for $1.5 billion, and GSK took over at SiranBio for up to a billion in milestone payments. Meanwhile, in Labiotech’s summary of the top funding rounds in May, companies like Apogee Therapeutics ($1.3 billion), CellCentirc ($220 million), CREAT Medicines ($122 million), Cytospire Therapeutics ($83 million) and Accro Bioscience ($50 million) were five of the ten largest private biotech funding rounds in the world.
Novo Nordisk Foundation launches €60.2m European incubator for cardiometabolic drug discovery
The new programme, called CardioMetabolic Bridge, will be backed with DKK450m (€60.2m) over six years. It is designed to identify promising university research in areas such as obesity, diabetes and cardiovascular disease, and develop it into projects that could become new therapies, spinouts or assets attractive to pharmaceutical companies and investors.
